Brind.
  1. NIH funding uncertainty affects Bio-Techne guidance.

PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.

2 reports, 2 independent Updated Jul 11
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.

Who's involved

What this event is mainly about
PDS Biotechnology (United States)National Cancer InstituteNational Institutes of HealthBioTech

How it developed

Newest first. Tap a step to see who reported it.
  1. PDS Biotechnology and NCI established a collaborative R&D agreement for oncology research.1 source
  2. NCI/NIH establishes collaborative R&D agreement with BioTech and appoints Chief of Surgical Oncology Section.1 source

Keep exploring

Part of

NIH funding uncertainty affects Bio-Techne guidance. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Clinical Trials ArenaPDS Biotechnology completes recruitment for stage one of colorectal cancer trial PDS Biotechnology has completed subject recruitment for stage one of its open-label Phase II trial, evaluating the sys
  • GlobeNewswirePDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results Metastatic Colorectal Cancer Cohort in